Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Announces Certain Preliminary 2021 Unaudited Financial Results
Preliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of  December 31, 2021 TUCSON, Ariz. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose
Toggle Summary HTG Completes HTP Product Next-Phase Development Milestone
Expands Potential Market and Study Opportunities for HTG Transcriptome Panel TUCSON, Ariz. , Dec. 22, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology,
Toggle Summary HTG Expands Therapeutics Scientific Advisory Board With Addition of Dr. Jerald Radich
Renowned Physician-Scientist Brings Significant Expertise as a Pioneer in the Fields of Leukemia Research and Molecular Genetics TUCSON, Ariz. , Dec. 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its
Toggle Summary HTG Announces Major Sales Milestone for HTG Transcriptome Panel
Recognizes More Than $1 Million of HTP Revenue Through November 2021 TUCSON, Ariz. , Dec. 09, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced
Toggle Summary HTG and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration
HTG’s Innovative Transcriptome Panel Technology to be Leveraged in Retrospective Studies TUCSON, Ariz. , Nov. 17, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

An amendment to the SC 13G filing

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities